Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.66 |
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | RAB9A | P51151 | 4/20 | 0.65 |
| ▸ | NPC1 | O15118 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5834186 | 0.90 | KMT2A (0.63) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL7122268 | 0.89 | KMT2A (0.56) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL7126565 | 0.86 | MAPT (0.67) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4092971 | 0.86 | KMT2A (0.71) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6709802 | 0.86 | TSHR (0.67) | KMT2AMEN1NPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL259597 | 0.85 | SMN1; SMN2 (0.73) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL882472 | 0.85 | RAB9A (0.67) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6431792 | 0.83 | PYGL (0.78) | KMT2AMEN1MAPT | |
| SCHEMBL7116503 | 0.83 | MAPT (0.66) | KMT2AMEN1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL7118343 | 0.82 | ABCG2 (0.54) | KMT2AMEN1RAB9ANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105218-A1 | CRTH2 Receptor Ligands For Therapeutic Use | 7TM PHARMA A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| US-20090105218-A1 | CRTH2 Receptor Ligands For Therapeutic Use | 7TM PHARMA A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| EP-1758571-A1 | CRTH2 RECEPTOR LIGANDS FOR THERAPEUTIC USE | 7TM Pharma A/S (DK) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005115374-A1 | CRTH2 RECEPTOR LIGANDS FOR THERAPEUTIC USE | 7TM PHARMA A/S (DK) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105218-A1 | CRTH2 Receptor Ligands For Therapeutic Use | NR1H2, NR1H3, HRH2 | KMT2A 2570/4885MEN1 2859/4885RAB9A 3947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.